gemcitabine has been researched along with sm 164 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Chen, G; You, L; Zhang, J; Zhang, TP; Zhao, YP; Zhou, B | 1 |
| Akara-Amornthum, P; Choksi, S; Jitkaew, S; Lomphithak, T; Tohtong, R | 1 |
3 other study(ies) available for gemcitabine and sm 164
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Therapy of Smac mimetic SM-164 in combination with gemcitabine for pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Caspase 3; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Triazoles; Xenograft Model Antitumor Assays | 2013 |
Key necroptotic proteins are required for Smac mimetic-mediated sensitization of cholangiocarcinoma cells to TNF-α and chemotherapeutic gemcitabine-induced necroptosis.
Topics: Biliary Tract Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Caspase Inhibitors; Cell Cycle Checkpoints; Cell Line, Tumor; Cholangiocarcinoma; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Necroptosis; Protein Kinases; Receptor-Interacting Protein Serine-Threonine Kinases; RNA Interference; RNA, Small Interfering; Triazoles; Tumor Necrosis Factor-alpha | 2020 |